Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
It will not replicate the appetite suppression of a GLP-1, but it can provide metabolic support during the transition
it's the absolute foundation of your work
Tirzepatide is best for people comparing top-end weight-loss potential and dual GIP/GLP-1 receptor activity
Marks BE, Williams KM, Sherwood JS, Putman MS
An interprofessional teamincluding endocrinologists, primary care clinicians, nurses, and pharmacistsis critical in optimizing patient outcomes using GLP-1 receptor agonists
Tirzepatide , a dual GIP/GLP-1 receptor agonist, has been approved in the UK for type 2 diabetes (as Mounjaro) but at the time of writing is not licensed by the MHRA specifically for weight management
